Respective prevalence of high-risk HPVgenotypes in cervical neoplasia in Senegal.
HPV negative cervical cancers
cervical neoplasia
high-risk HPV
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
27
03
2021
received:
10
02
2021
accepted:
12
04
2021
pubmed:
15
4
2021
medline:
26
11
2021
entrez:
14
4
2021
Statut:
ppublish
Résumé
With the perspective of prophylactic vaccination against high-risk human papillomavirus (HPV), we analyzed the viral epidemiology of cervical neoplasia in Senegal. All patients were treated at the Institut Joliot Curie du Cancer in Dakar. HPV genotypes were characterized using a real-time polymerase chain reaction-based approach and sequencing. Histologically, there were 224 invasive carcinomas, 17 high-grade intraepithelial neoplasia (CIN), and five undetermined histologies. Molecular analysis was conclusive in 241 cases. HPV DNA was found in 207/241 (85.9%) cases while 34/241 (14.1%) remained HPV negative. There was one single genotype in 127/207 (61.4%) cases and several in 80/207 (38.6%) corresponding to 308 genotypes identified. Viral genotyping found HPV16 in 175 (56.8%) cases, HPV18 in 45 (14.6%), HPV45 in 40 (13.0%), HPV58 in 35 (11.4%), HPV33 in 6 (2.0%), HPV35 in 3 (1.0%), HPV31 in 2 (0.6%), HPV39 and HPV56 in one (0.3% each). Our analysis showed that 98.4% of the HPV-positive cases were associated with viral genotypes covered by the 9-valent HPV vaccine. However, 14.1% of cases remained HPV negative. Therefore, prophylactic vaccination using a 9-valent vaccine should dramatically reduce the incidence of HPV-associated neoplasia but the detection and treatment of CIN remain necessary for the optimal prevention of cervical cancer.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5110-5117Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bray F , Ferlay J , Soerjomataram I , Siegel RL , Torre LA , Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Arbyn M , Weiderpass E , Bruni L , et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191-e203.
Walboomers JM , Jacobs MV , Manos MM , et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
Schiffman M , Castle PE , Jeronimo J , Rodriguez AC , Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
de Sanjose S , Quint WG , Alemany L , et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
Serrano B , de Sanjose S , Tous S , et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51:1732-1741.
de Martel C , Plummer M , Vignat J , Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664-670.
Macgregor JE , Campbell MK , Mann EM , Swanson KY . Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease. BMJ. 1994;308:1407-1411.
Harper DM , Franco EL , Wheeler CM , et al. HPV Vaccine Study group Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
Malagón T , Drolet M , Boily MC , et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781-789.
Westra TA , Stirbu-Wagner I , Dorsman S , et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013;13:75.
LaMontagne DS , Bloem PJN , Brotherton JML , Gallagher KE , Badiane O , Ndiaye C. Progress in HPV vaccination in low- and lower-middle-income countries. Int J Gynaecol Obstet. 2017;138(Suppl 1):7-14.
de Sanjose S , Brotons M , LaMontagne DS , Bruni L. Human Papillomavirus vaccine disease impact beyond expectations. Curr Opin Virol. 2019;39:16-22.
Kind AB , Pavelyev A , Kothari S , et al. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland. BMC Public Health. 2020;20:671.
Signorelli C , Odone A , Ciorba V , et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145:1962-1982.
Brisson M , Kim JJ , Canfell K , et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575-590.
Mbaye ElHS , Gheit T , Dem A , et al. Human papillomavirus infection in women in four regions of Senegal. J Med Virol. 2014;86:248-256.
Diop-Ndiaye H , Beiter K , Gheit T , et al. Human Papillomavirus infection in senegalese female sex workers. Papillomavirus Res. 2019;7:97-101.
Xi LF , Toure P , Critchlow CW , et al. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. Int J Cancer. 2003;103:803-897.
Ndiaye C , Alemany L , Ndiaye N , et al. Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences? S.Trop Med Int Health. 2012;17:1432-1440.
Berthet N , Berling C , Nabi H , et al. COFAC-Col: a cervical cancer control networking initiative in five French-speaking African countries. Cancer Epidemiol Biomarkers Prev. 2016;25:1004-1005.
Berois N , De Cremoux P , Mazal D , et al. Prevalence and distribution of high-risk human papillomavirus genotypes in invasive carcinoma of the uterine cervix in Uruguay. Int J Gynecol Cancer. 2013;23:527-532.
Gallagher KE , LaMontagne DS , Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36:4761-4767.
Garland SM , Pitisuttithum P , Ngan HYS , et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries. J Infect Dis. 2018;218:95-108.
Lei J , Ploner A , Elfström KM , et al. HPV vaccination and the risk of invasive cervical cancer. Engl J Med. 2020;383:1340-1348.
Aho J , Hankins C , Tremblay C , et al. Canadian Women's HIV Study Group Genomic polymorphism of human papillomavirus type 52 predisposes toward persistent infection in sexually active women. J Infect Dis. 2004;190:46-52.
Formentin A , Archambault J , Koushik A , et al. Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix. Int J Cancer. 2013;132:1821-1830.
Li J , Wang YY , Nan X , et al. Prevalence of human papillomavirus genotypes among women with cervical lesions in the Shaanxi Province of China. Gent Mol Res. 2016;15:1-9.
Nogueira Dias Genta ML , Martins TR , Mendoza Lopez RV , et al. Multiple HPV genotype infection impact on invasive cervical cancer presentation and survival. PLOS One. 2017;12:e0182854.
Kabir A , Bukar M , Nggada HA , Rann HB , Gidado A , Musa AB . Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri. Nigeria. Pan Afr Med J. 2019;33:284.
Sakamoto J , Kamiura S , Okayama K , et al. Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res. 2018;6:46-51.
Obiri-Yeboah D , Akakpo PK , Mutocheluh M , et al. Epidemiology of cervical human papillomavirus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. BMC Cancer. 2017;17:688.
Camargo M , Del Río-Ospina L , Soto-De León SC , et al. Association of HIV status with infection by multiple HPV types. Trop Med Int Health. 2018;23:1259-1268.
Harlé A , Guillet J , Thomas J , et al. HPV insertional pattern as a personalized tumor marker for the optimized tumor diagnosis and follow-up of patients with HPV-associated carcinomas: a case report. BMC Cancer. 2019;19:277.
Nicolás I , Marimon L , Barnadas E , et al. HPV-negative tumors of the uterine cervix. Mod Pathol. 2019;32:1189-1196.
Lei J , Ploner A , Lagheden C , et al. High-risk human papillomavirus status and prognosis in invasive cervical cancer: a nationwide cohort study. PLOS Med. 2018;15(10):e1002666.
Gravitt EP , Winer RL . Natural history of HPV infection across the lifespan: role of viral latency. Viruses. 2017;9(10):267.